This report provides comprehensive coverage of the global CNS market, incorporating disease overview, epidemiological analyses of the major indications, and market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading CNS brands are assessed and five of the market' s leading players are profiled.
Antipsychotics were the largest CNS drug class with $24.2bn sales, a 33.9% share of the market in 2010. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016.
Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patents and safeguard revenue streams. Companies have also begun to manufacture and market generic versions of their products.
Of the indications in the CNS category, Alzheimer' s disease (AD) represents the main area of R&D interest for pharmaceutical companies, with an estimated 288 compounds in various stages of development.